Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
Those taking the drugs for at least three years cut their risk of heart attack, stroke or cardiac death by 20 per cent ...
The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people ...
Ozempic could dramatically reduce the risk of heart attacks and stroke, a new study indicates. The weight loss jab has become ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
Semaglutide once a week reduced risk of adverse outcomes in kidney patients by 24 percent, finds study published in The New ...
A study has found the anti-obesity drug sold under brand names Wegovy, Ozempic and Rybelsus could reduce the risk of heart attacks, strokes ...
An obesity drug could cut heart disease and stroke risks even if you don’t lose any weight. New research has shown that ...
As a major study shows it cuts heart attack risks experts say semaglutide could 'transform many chronic diseases of ageing' ...
New analyses of a large trial presented at the European Congress on Obesity showed the clear benefits of the popular ...